Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Thermo Fisher Scientific, Inc.: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Thermo Fisher Scientific, Inc.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Thermo Fisher Scientific, Inc.
  • The company is in debt and has limited leeway for investment
  • The firm trades with high earnings multiples: 23.52 times its 2026 earnings per share.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Rating Financials

Thermo Fisher Scientific, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Thermo Fisher Scientific, Inc. SectorUnited States

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Thermo Fisher Scientific, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Thermo Fisher Scientific, Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Thermo Fisher Scientific, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
175B
BBB
148B
BBB
130B
A
72.39B
BBB
49.43B
AAA
44.28B
BBB
37.48B
AA
35.67B
AAA
29.42B
A
27.89B
A
Average 74.92B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. TMO Stock
  4. Ratings Thermo Fisher Scientific, Inc.
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW